Mediator Kinase Inhibition Sensitizes AML Models to Venetoclax

Company Academic investigators (Leukemia) Event Type Peer-reviewed publication (Leukemia) Modality Small molecule (preclinical) Asset AML874 Target CDK8/19 (Mediator kinase module); BCL2 (combination) Disease Area Acute myeloid leukemia (FLT3-mutant subset) Summary A peer-reviewed Leukemia paper published online November 11 identifies CDK8/19 Mediator kinase inhibition as an…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *